Literature DB >> 19018714

BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia.

Janusz K Rybakowski1.   

Abstract

The brain-derived neurotrophic factor (BDNF) gene has become a candidate gene for molecular-genetic studies of mood disorders and schizophrenia, and also for pharmacogenomics of drugs used in the treatment of these conditions, such as mood-stabilizers in bipolar mood disorder, antidepressants in depression, and antipsychotics in schizophrenia. It has been demonstrated that the functional Val66Met polymorphism of the gene can be associated with a number of clinical and pharmacological phenomena in these illnesses.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19018714     DOI： 10.2217/14622416.9.11.1589

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  42 in total

1.  Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.

Authors:  Francesco Matrisciano; Patricia Tueting; Stefania Maccari; Ferdinando Nicoletti; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

2.  Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits.

Authors:  A Terracciano; B Martin; D Ansari; T Tanaka; L Ferrucci; S Maudsley; M P Mattson; P T Costa
Journal:  Genes Brain Behav       Date:  2010-03-22       Impact factor: 3.449

Review 3.  Secreted factors as synaptic organizers.

Authors:  Erin M Johnson-Venkatesh; Hisashi Umemori
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

Review 4.  The Val66Met brain-derived neurotrophic factor gene variant interacts with early pain exposure to predict cortisol dysregulation in 7-year-old children born very preterm: Implications for cognition.

Authors:  C M Y Chau; I L Cepeda; A M Devlin; J Weinberg; R E Grunau
Journal:  Neuroscience       Date:  2015-08-28       Impact factor: 3.590

Review 5.  Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts.

Authors:  Christoph van Thriel; Remco H S Westerink; Christian Beste; Ambuja S Bale; Pamela J Lein; Marcel Leist
Journal:  Neurotoxicology       Date:  2011-10-12       Impact factor: 4.294

6.  The brain-derived neurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis.

Authors:  Yu Pei; Alicia K Smith; Yongjun Wang; Yanli Pan; Jian Yang; Qi Chen; Weigang Pan; Feng Bao; Lisha Zhao; Changle Tie; Yizheng Wang; Jian Wang; Wenfeng Zhen; Jinxia Zhou; Xin Ma
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-18       Impact factor: 3.568

Review 7.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

8.  The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.

Authors:  K J Burghardt; R Pop-Busui; M J Bly; T B Grove; S F Taylor; V L Ellingrod
Journal:  Clin Transl Sci       Date:  2012-11-01       Impact factor: 4.689

9.  Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.

Authors:  Mingqing Xu; Sheng Li; Qinghe Xing; Rui Gao; Guoyin Feng; Zhiguang Lin; David St Clair; Lin He
Journal:  Eur J Hum Genet       Date:  2010-01-20       Impact factor: 4.246

Review 10.  Lithium's role in neural plasticity and its implications for mood disorders.

Authors:  J D Gray; B S McEwen
Journal:  Acta Psychiatr Scand       Date:  2013-04-26       Impact factor: 6.392
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.